Cage Pharma, founded in 2017, is a pre-clinical biopharmaceutical company focused on developing innovative anti-cancer drugs that target tumor metabolism. The company's core mission is to create effective cancer treatments with controlled toxicity profiles. Their flagship product is an encapsulated anti-cancer agent formulated with 3-bromopyruvate, which targets tumor glycolysis, a key hallmark of cancer. This approach aims to provide medical practitioners with more effective and safer treatment options for cancer patients.

Cage Pharma has attracted notable interest from the medical and scientific communities due to its novel approach to cancer treatment. While specific investors and affiliated individuals are not detailed, the company's progress in pre-clinical stages marks significant achievements in the biopharmaceutical field. Cage Pharma's work has the potential to make a substantial impact on cancer therapy by offering new, targeted solutions that could improve patient outcomes and reduce side effects associated with traditional treatments.